LIGAND PHARMACEUTICALS INCORPORATED Business Combination, Acquisition Related Costs
LIGAND PHARMACEUTICALS INCORPORATED (LGND) reported Business Combination, Acquisition Related Costs of $0 for the 18-month period ending 2020-06-30, per its 10-Q filed 2020-08-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationAcquisitionRelatedCosts · last filed 2020-08-07
- 2020-06-30: Business Combination, Acquisition Related Costs 18 month $0.00.
| Period end | Business Combination, Acquisition Related Costs 18 month |
|---|---|
| 2020-06-30 | $0.00 10-Q · filed 2020-08-07 |